Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
China Opens Door to Stronger U.S. Trade Ties Amid Rising Tensions 
The pandemic is still disrupting young people’s careers 
Dollar Strengthens as U.S.-Iran Peace Talks Send Mixed Signals 
Disaster or digital spectacle? The dangers of using floods to create social media content 
Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Why have so few atrocities ever been recognised as genocide? 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Why financial hardship is more likely if you’re disabled or sick 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Golden Dome Missile Defense: Anduril and Palantir Join Forces on Trump's $185B Space Shield 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
